Search Results - David Paling

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis... by Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, Vasileios Kontogiannis, Amir Ansaripour, Wallace Brownlee, Wallace Brownlee, David Paling, Mehdi Javanbakht

    Published in Frontiers in Neurology (2024-12-01)
    Get full text
    Article


  2. 2

    Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial by David Paling, Basil Sharrack, Joyutpal Das, Kathleen Baster, Chayaporn Chotiyarnwong, Krishnan Nair, Lorenza Angelini, Ellen Buckley, Claudia Mazza, Daniel Heyes, Ridha Ramiz, Azza Ismail, Ali Ali, Ralf Lindert, Sian Price

    Published in BMJ Neurology Open (2020-07-01)
    Get full text
    Article


  3. 3

    Brain reserve and physical disability in secondary progressive multiple sclerosis by Nevin John, Jeremy Chataway, Jacqueline Palace, Gavin Giovannoni, David Paling, Frederik Barkhof, Floriana De Angelis, Lorraine Smith, Thomas Williams, Martin Duddy, James Overell, Basil Sharrack, Sebastien Ourselin, Allan Walker, Siddharthan Chandran, Richard Nicholas, Shuna Colville, Peter Connick, Carolyn Young, Jeremy Hobart, Anisha Doshi, Sharmilee Gnanapavan, Helen Ford, Baljean Dhillon, Thanh Phan, Arman Eshaghi, Julia Aram, Nigel Stallard, James Cameron, Brendan McLean, Matthew Craner, Domenico Plantone, Jonathan Stutters, Ferran Prados Carrasco, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Clive Hawkins, Roger Bastow, Daisy Mollison, Waqar Rashid, Joe Guadagno, Nikolaos Evangelou, Seema Kalra, Alberto Calvi, Yingtong Li, Tiggy Beyene, Vanessa Bassan, Alvin Zapata, Dawn Lyle, Heinke Arndt

    Published in BMJ Neurology Open (2024-09-01)
    Get full text
    Article


  4. 4

    Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (Star... by Gavin Giovannoni, Stephen J Walters, David Paling, Olga Ciccarelli, Cindy Cooper, Eli Silber, Martin Duddy, Hannah Hunter, David Hunt, Basil Sharrack, Paul Gallagher, Ian Galea, Richard Nicholas, Annalena Venneri, Neil Robertson, Carolyn Young, Jeremy Hobart, David Rog, Ben Turner, Muhammad Saif, Azza Ismail, Gavin Brittain, John A Snowden, Diana Papaioannou, Alasdair J Coles, Gordon Mazibrada, Neil Scolding, Maruthi Vinjam, Matthew Bursnall, Claire Rice, Ian Pomeroy, Majid Kazmi, Esmaeil Nikfekr, Kim Orchard, Thushan de Silva, Jennifer Petrie, Elisa Roldan, Caroline Besley, Kate E M Duffy, Rachel Glover, Katie Hullock, Colette Beecher, Ian Gabriel, Charalampia Kyriakou, Andy Peniket, Paolo A Muraro, Amy Publicover, Andy Clark, Charles Crawley, Eleni Tholouli, Fran Kinsella, Gabriele De Luca, Jeff Davies, Jenny Byrne, Keith Campbell, Leonora Finisku, Simon Bulley, Vic Campbell

    Published in BMJ Open (2024-02-01)
    Get full text
    Article


Search Tools: